



Mapping


胃


担当：長江麻由


白色光
(5枚)















インジゴカルミン散布
(3枚)












NBI
(10枚)






























(NBI)



内視鏡診断

大きさ：15mm

肉眼型：0-II c、未分化型

深達度：M、UL：(-)

NBI観察：DL(+)


微小血管構造：irregular

表面微細構造：irregular


送気脱気で変形は容易

ESD


ESD前




マーキング



ESD後






肛門側



口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側





肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側



13




1



肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側





肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側




Key slice



肛門側 ←



→ 口側






肛門側 ←



→ 口側








肛門側 ←







→ 口側



















肛門側 ←



→ 口側






肛門側 ←



→ 口側








肛門側 ←







→ 口側































肛門側 ←



→ 口側






肛門側 ←



→ 口側








肛門側 ←







→ 口側























AE1/AE3





EVG

脈管侵襲陰性
リンパ管侵襲陰性




D2-40

desmin



粘膜筋板下端から浸潤最深部まで
約1400 μ m(SM2)



深部断端陰性

病理診断

Stomach ESD: poorly differentiated adenocarcinoma,
non-solid type(por2>>tub2), pT1b(SM2,1.4mm),
INFb, Ly0, V0, pUL0, pHM0, pVM0

e-Cure C


Mapping



肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側





肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側




tub2
por2



肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側






肛門側 ←



→ 口側




tub2
por2




肛門側 ←




→ 口側



— SM



— tub2
— por2



— SM

eCura system

リスク分類	合計点	リンパ節転移率	5年転移再発率 (無治療経過観察時)	5年癌特異的生存率 (無治療経過観察時)
低リスク	0-1点	2.5%	0.7%	99.6%
中リスク	2-4点	6.7%	5.7%	96.0%
高リスク	5-7点	22.7%	11.7%	90.1%

3点:リンパ管侵襲

1点:腫瘍径>30mm, VM(+), SM2, 静脈侵襲


0点:未分化型優位, UL(+)

本症例：未分化型優位（0点）、SM2（1点）⇒計1点（低リスク）??


eCura systemは分化型癌を中心に用いるのが望ましいとされている

External Validation of the eCura System for Undifferentiated-Type Early Gastric Cancer with Noncurative Endoscopic Resection


Hyo-Joon Yang¹, Young-Il Kim², Ji Yong Ahn³, Kee Don Choi³, Sang Gyun Kim⁴, Seong Woo Jeon⁵, Jie-Hyun Kim⁶, Sung Kwan Shin⁷, Hyuk Lee⁸, Wan Sik Lee⁹, Gwang Ha Kim¹⁰, Jae Myung Park¹¹, Woon Geon Shin¹², and Il Ju Choi²




Characteristic	Radical surgery group (n=270)				No additional treatment group (n=364)			
	Low-risk (n=151)	Intermediate- risk (n=92)	High-risk (n=27)	p-value	Low-risk (n=317)	Intermediate- risk (n=42)	High-risk (n=5)	p-value
Age, yr	57.6 [51.1–66.7]	62.8 [55.6–70.4]	59.8 [52.4–71.8]	0.017	63.1 [53.0–72.5]	69.9 [54.8–78.4]	75.4 [72.2–79.6]	0.005
Male sex	93 [61.6]	57 [62.0]	22 [81.5]	0.132	185 [58.4]	27 [64.3]	1 [20.0]	0.695
ASA physical status				0.165				0.035
I	93 [61.6]	48 [52.2]	17 [63.0]		176 [55.5]	19 [45.2]	3 [60.0]	
II	57 [37.7]	38 [41.3]	8 [29.6]		125 [39.4]	15 [35.7]	1 [20.0]	
III–IV	1 [0.7]	6 [6.5]	2 [7.4]		16 [5.1]	8 [19.1]	1 [20.0]	
Tumor location				0.247				0.511
Upper third	61 [40.4]	43 [46.7]	13 [48.2]		119 [37.5]	16 [38.1]	2 [40.0]	
Middle third	71 [47.0]	42 [45.7]	11 [40.7]		173 [54.6]	20 [47.6]	2 [40.0]	
Lower third	19 [12.6]	7 [7.6]	3 [11.1]		25 [7.9]	6 [14.3]	1 [20.0]	
Tumor size, mm	26.0 [20.0–35.0]	23.0 [18.0–33.0]	35.0 [18.0–44.0]	0.014	26.0 [22.0–34.0]	25.5 [17.5–36.0]	24.0 [21.5–42.3]	0.872
Depth of invasion				<0.001				<0.001
Mucosa	85 [56.3]	13 [14.1]	0		233 [73.5]	8 [19.1]	0	
Submucosa <500 µm	27 [17.9]	20 [21.8]	0		45 [14.2]	5 [11.9]	0	
Submucosa ≥500 µm	39 [25.8]	59 [64.1]	27 [100.0]		39 [12.3]	29 [69.0]	5 [100.0]	
Histology				0.003 [†]				0.019 [†]
PD	112 [74.2]	74 [80.4]	24 [88.9]		195 [61.5]	30 [71.4]	4 [80.0]	
SRC	39 [25.8]	14 [15.2]	1 [3.7]		118 [37.2]	10 [23.8]	0	
Mucinous	0	4 [4.4]	2 [7.4]		4 [1.3]	2 [4.8]	1 [20.0]	
Lymphovascular invasion	0	49 [53.3]	27 [100.0]	<0.001	0	18 [42.9]	5 [100.0]	<0.001
Ulceration	15 [9.9]	10 [10.9]	2 [7.4]	0.856	32 [10.1]	4 [9.5]	1 [20.0]	0.749
Positive vertical margin	4 [2.6]	33 [35.9]	17 [63.0]	<0.001	5 [1.6]	17 [40.5]	4 [80.0]	<0.001




■追加治療なし群
低リスク：92.7%
中リスク：68.9%
高リスク：80.0%
⇒有意差あり
($p < 0.001$)



■根治手術群
有意差なし



■追加治療なし群
低リスク：99.7%
中リスク：94.7%
高リスク：80.0%
⇒有意差あり
($p < 0.001$)



■根治手術群
有意差なし

Risk category	Overall mortality				Cancer-specific mortality				Cancer recurrence			
	Person time at risk, mo	No. of cases	HR (95% CI)	p-value	Person time at risk, mo	No. of cases	HR (95% CI)	p-value	Person time at risk, mo	No. of cases	HR (95% CI)	p-value
Low-risk	27,145	31	1		27,145	1			18,563	3		
Intermediate-risk	3,342	15	2.80 [1.45-5.40]	0.002	3,342	3	49.39 [2.95-826.70]	0.007	2,004	3	12.63 [1.91-83.31]	0.008
High-risk	346	2	4.61 [1.01-21.08]	0.049	346	1	586.83 [6.81-50,574]	0.005	195	1	57.32 [2.37-1,384]	0.013
Overall p-value				0.004				0.011				0.011
p for trend			2.48 [1.46-4.21]	0.001			27.45 [3.27-230.26]	0.002			8.98 [2.16-37.32]	0.003

未分化癌にeCura systemは適用できる？

✓低リスク患者のLN転移率：2.6%

⇒低リスク・追加治療なしの患者は、高いCSS率(5年で99.7%)と癌再発リスクの低さ(5年で0.8%)を示し、非治癒切除でも**慎重な経過観察**で可？

✓中リスク患者のLN転移率：10.9%

⇒全死亡率、CSS率、癌再発率は低リスク患者よりも有意に高く、**追加手術が推奨**

✓高リスク患者のLN転移率：14.8%

⇒選択バイアスにより過少評価されている可能性あり。全死亡率、CSS率、癌再発率は著しく高いため、**追加手術が推奨**

eCura systemは未分化癌にも適応できることが示唆